Targeted oral delivery technologies include conventional pH-sensitive enteric coatings, multi-matrix, osmotic-controlled and timed-release methods. Limitations include variable or off-target delivery, reduced potency, leakage from one site to another, lack of patent protection and manufacturing complexity, as well as high COGS. GEMICEL overcomes these challenges cost-effectively based on its single- or dual-targeted drug delivery platform. This patented delivery technology is based on dual polymer layers programmed to dissolve at specific pH and peristaltic pressure levels. GEMICEL in various oral forms delivers drugs and biologics to specific target locations in the GI tract. This technology is perfectly designed to target the microbiome with products which otherwise cannot achieve their intended effects. As an innovation it effectively addresses unmet medical needs across multiple-therapeutic areas.

Scintigraphy studies were conducted in 27 healthy volunteers. GRAS ingredients available and scale-up completed. Phase I and IB studies were initiated in 24 subjects before Abbvie ended the ulcerative colitis study following AbbVie’s acquisition of Allergan. Human clinical scintigraphy studies confirmed that GEMICEL is highly tunable and reliably delivers high therapeutic payloads.